| http://purl.uniprot.org/citations/37843557 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/37843557 | http://www.w3.org/2000/01/rdf-schema#comment | "Lung cancer has been the main cause of cancer mortality worldwide. Furthermore, lung cancer rates of new cases per year evidenced a large incidence of this neoplasm in both men and women. Because there is no biomarker for early detection, it is frequently detected late, at an advanced state. The introduction of multiple lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations has modified the therapy of lung cancer. Immunotherapy advances have resulted in substantial improvements in overall survival and disease-free survival, making immune checkpoint inhibitors (ICIs) a potential option for lung cancer treatment. Current PD-1/PD-L1/CTLA-4 immunotherapies have resulted in important response and survival rates. However, existing medicines only function in around 20% of unselected, advanced NSCLC patients, and primary and acquired resistance remain unsolved obstacles. Therefore, precise predictive indicators must be identified to choose the best patients for ICI treatment. Thus, Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) stands out as a potential tumor biomarker, with distinctive expression in normal tissues, in tumor immune involvement, and a high structural similarity to PD-L1. Understanding the tumor immune response and the search for new therapeutic targets leads to the improvement of therapeutic pathways directed at the tumor microenvironment. The present review aims to analyze Siglec-15 potential as a diagnostic, prognostic, and response biomarker in lung cancer, considering its results evidenced in the current literature."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.org/dc/terms/identifier | "doi:10.1007/s00432-023-05437-z"xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "de Melo Rego M.J.B."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "Pereira M.C."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "da Silva T.D."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "da Silva M.M."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "da Rocha Pitta M.G."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "Cordeiro G.G."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "Mattos-Jr L.A.R."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "Moreira R.S."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/author | "de Melo Vasconcelos C.F."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/date | "2023"xsd:gYear |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/name | "J Cancer Res Clin Oncol"xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/pages | "17651-17661"xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/title | "Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer."xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://purl.uniprot.org/core/volume | "149"xsd:string |
| http://purl.uniprot.org/citations/37843557 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/37843557 |
| http://purl.uniprot.org/citations/37843557 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/37843557 |
| http://purl.uniprot.org/uniprot/#_A7E1W7-mappedCitation-37843557 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/37843557 |
| http://purl.uniprot.org/uniprot/#_Q6ZMC9-mappedCitation-37843557 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/37843557 |
| http://purl.uniprot.org/uniprot/A7E1W7 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/37843557 |
| http://purl.uniprot.org/uniprot/Q6ZMC9 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/37843557 |